Clinical Trials Browser

Phase 3 × Interventional × Papillomavirus Vaccines × Clear all

Papillomavirus Infections

NCT05668572 2023-01-04

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Phase 3 Unknown

12,000 enrolled

Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05173324 2022-08-03

H2VICTORY

Phase 3 Not yet recruiting

8,000 enrolled

HIV Infections, Papillomavirus Infections

NCT01735006 2020-02-24

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Phase 3 Completed

7,372 enrolled

Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

Phase 3 Completed

1,518 enrolled 44 charts

Papillomavirus Infections

NCT00552279 2018-06-25

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Phase 3 Completed

805 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Phase 3 Completed

600 enrolled 12 charts

Papillomavirus Infections

NCT00092521 2015-09-25

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Phase 3 Completed

5,759 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00501137 2015-04-10

BCGov-01

Phase 3 Completed

830 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00325130 2015-03-12

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Phase 3 Completed

1,042 enrolled 26 charts

Diphtheria, Meningitis, Neoplasms, Glandular and Epithelial, Tetanus, Whooping Cough

Clinical Trials

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

H2VICTORY

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

V503-010

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

BCGov-01

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)